Stock LSL LSL PHARMA GROUP INC.
Add to a list
To use this feature you must be a member
Log inSign up

LSL Pharma Group Inc. Share Price

Equities

LSL

CA50190N1042

Pharmaceuticals

End-of-day quote Toronto S.E.
Other stock markets
 23:00:00 16/05/2024 BST 		5-day change 1st Jan Change
0.49 CAD 0.00% Intraday chart for LSL Pharma Group Inc. -2.00% +1.03%
05-06 LSL Pharma to Acquire Quebec Competitor for $2.5 Million to Expand Natural-Product Offerings MT
05-06 LSL Pharma Group Inc. entered into a binding Letter of Intent to acquire Target Co for CAD 2.5 million. CI

Financials

Sales 2021 8.77M 6.44M 507M Sales 2022 8.21M 6.03M 475M Capitalization 53.06M 38.95M 3.07B
Net income 2021 -1M -734K -57.85M Net income 2022 -8M -5.87M -463M EV / Sales 2021 * -
Net cash position 2021 * - 0 0 Net cash position 2022 * - 0 0 EV / Sales 2022 * -
P/E ratio 2021 *
-
P/E ratio 2022 *
-
Employees -
Yield 2021 *
-
Yield 2022 *
-
Free-Float 97.42%
More Fundamentals * Assessed data

Chart LSL Pharma Group Inc.

Dynamic Chart

Latest news about LSL Pharma Group Inc.

LSL Pharma to Acquire Quebec Competitor for $2.5 Million to Expand Natural-Product Offerings MT
LSL Pharma Group Inc. entered into a binding Letter of Intent to acquire Target Co for CAD 2.5 million. CI
LSL Pharma Group Brief: Said Earlier Wednesday It Secured $3.8 Million As the Second And Final Tranche Of Its Private Placement Of Units MT
LSL Pharma Group Inc. announced that it has received CAD 6.479426 million in funding from Alfera Pharmaceuticals, LLC CI
LSL Pharma Group Inc. Appoints Diane Beaudry and Mario Paradis to Its Board of Directors CI
LSL Pharma Group Brief: Has Upsized Its Private Placement From $3.5 Million To $7.5 Million MT
LSL Pharma Loses 5% As Raises $6.44 Million In First Closing Of Private Placements MT
LSL Pharma Raises $6.44 Million In First Closing Of Private Placements MT
LSL Pharma Group Inc. announced that it expects to receive CAD 3.5 million in funding CI
LSL Pharma Group Announced An Extension Of Its Convertible Debentures Offering MT
LSL Pharma Group Up 4.7% After Reporting Closing of Second Tranche of Convertible Debentures Offering MT
LSL Pharma Group Appoints Luc Mainville as Chief Financial Officer MT
LSL Pharma Group Inc. Appoints Luc Mainville as Chief Financial Officer, Effective December 4, 2023 CI
LSL Pharma Group Inc. Appoints Luc Mainville as Senior Vice President, Effective December 4, 2023 CI
LSL Pharma Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
More news

Press releases LSL Pharma Group Inc.

LSL Pharma Group Enters Into Binding Agreement to Acquire Quebec Competitor GL
LSL Pharma Group Reports Its Fourth Quarter and Year-End 2023 Results and Highlights GL
LSL Pharma Group Reports Its Fourth Quarter and Year-End 2023 Results and Highlights AQ
LSL Pharma Group Secures $3.8 Million as the Second and Final Tranche of Its Private Placement of Units GL
LSL Pharma Group Announces the Addition of New Members to Its Board of Directors GL
More press releases

News in other languages on LSL Pharma Group Inc.

Gestion Jacques Grimard Inc. acquiert des unités de Groupe LSL Pharma Inc.
Le Groupe LSL Pharma clôture un financement de 6,44 millions $ comme première tranche de placements privés concomittants sans courtier
Le groupe LSL Pharma annonce une combinaison de placements privés pour un produit brut total maximum de 8 millions $
Le Groupe LSL Pharma annonce la prolongation de son placement de débentures convertibles
Le Groupe LSL Pharma annonce la clôture de la deuxième tranche du placement de débentures convertibles
More news

Quotes and Performance

1 week-2.00%
Current month+16.67%
1 month+19.51%
3 months+16.67%
6 months+19.51%
Current year+1.03%
More quotes

Highs and lows

1 week
0.46
Extreme 0.46
0.50
1 month
0.39
Extreme 0.39
0.55
Current year
0.35
Extreme 0.35
0.55
1 year
0.35
Extreme 0.35
0.57
3 years
0.35
Extreme 0.35
1.00
5 years
0.35
Extreme 0.35
1.00
10 years
0.35
Extreme 0.35
1.00
More quotes

Company Profile

LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company. The Company is specializing in the development, manufacturing and distribution of natural health products and dietary supplements in solid dosage forms, as well as sterile ophthalmic pharmaceutical products. The Company’s subsidiaries include Steri-Med Pharma Inc., LSL Laboratory Inc. and Groupe Immobilier LSL inc.
Sector
Pharmaceuticals
Calendar
27/06/2024 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

1st Jan change Capi.
LSL PHARMA GROUP INC. Stock LSL Pharma Group Inc.
+1.03% 38.95M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.09% 694B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.39% 593B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.34% 371B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 331B
ABBVIE INC. Stock AbbVie Inc.
+7.39% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.25% 239B
ROCHE HOLDING AG Stock Roche Holding AG
-3.03% 209B
NOVARTIS AG Stock Novartis AG
+10.02% 209B
AMGEN INC. Stock Amgen Inc.
+8.49% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LSL Stock